Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in Non-Inotrope-Dependent Advanced Heart Failure Patients: Insights from the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients)

Circulation: Heart Failure

Volumn 10, Issue 5, 2017, Pages

  Lanfear, David E ^a   Levy, Wayne C ^b   Stehlik, Josef ^c   Estep, Jerry D ^d   Rogers, Joseph G ^e   Shah, Keyur B ^f   Boyle, Andrew J ^g   Chuang, Joyce ^h   Farrar, David J ^h   Starling, Randall C ⁱ  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

^e DUKE UNIVERSITY   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h St Jude Medical Inc   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

Author keywords

area under the curve; death; heart failure; survival analysis

Indexed keywords

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR MORTALITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEARTMATE II RISK SCORE; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODEL; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCORING SYSTEM; SEATTLE HEART FAILURE MODEL; SURVIVAL RATE; TREATMENT OUTCOME; CLINICAL TRIAL; DISEASE MANAGEMENT; EPIDEMIOLOGY; FOLLOW UP; HEART ASSIST DEVICE; HEART VENTRICLE; MORTALITY; MULTICENTER STUDY; OUTPATIENT; PROCEDURES; RISK FACTOR; TRENDS; UNITED STATES;

AGED; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART VENTRICLES; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 85019548781     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.116.003745     Document Type: Article

References (21)

1. John R, Kamdar F, Liao K, Colvin-Adams M, Boyle A, Joyce L. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. Ann Thorac Surg. 2008;86:1227-1234; discussion 1234. doi: 10.1016/j. athoracsur.2008.06.030.
2. Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, Conte JV, Naka Y, Mancini D, Delgado RM, MacGillivray TE, Farrar DJ, Frazier OH; HeartMate II Clinical Investigators. Use of a continuousflow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885-896. doi: 10.1056/NEJMoa067758.
3. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM 3rd, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH; HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251. doi: 10.1056/NEJMoa0909938.
4. Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC Jr, Colombo PC, Walsh MN, Milano CA, Patel CB, Jorde UP, Pagani FD, Aaronson KD, Dean DA, McCants K, Itoh A, Ewald GA, Horstmanshof D, Long JW, Salerno C; MOMENTUM 3 Investigators. A fully magnetically levitated circulatory pump for advanced heart failure. N Engl J Med. 2017;376:440-450. doi: 10.1056/NEJMoa1610426.
5. Estep JD, Starling RC, Horstmanshof DA, Milano CA, Selzman CH, Shah KB, Loebe M, Moazami N, Long JW, Stehlik J, Kasirajan V, Haas DC, O'Connell JB, Boyle AJ, Farrar DJ, Rogers JG; ROADMAP Study Investigators. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study. J Am Coll Cardiol. 2015;66:1747-1761. doi: 10.1016/j.jacc.2015.07.075.
6. Jorde UP, Kushwaha SS, Tatooles AJ, Naka Y, Bhat G, Long JW, Horstmanshof DA, Kormos RL, Teuteberg JJ, Slaughter MS, Birks EJ, Farrar DJ, Park SJ; HeartMate II Clinical Investigators. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63:1751-1757. doi: 10.1016/j.jacc.2014.01.053.
7. Boyle AJ, Ascheim DD, Russo MJ, Kormos RL, John R, Naka Y, Gelijns AC, Hong KN, Teuteberg JJ. Clinical outcomes for continuousflow left ventricular assist device patients stratified by pre-operative INTERMACS classification. J Heart Lung Transplant. 2011;30:402-407. doi: 10.1016/j.healun.2010.10.016.
8. Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidley DE, Ewald GA, Sundareswaran KS, Farrar DJ, Slaughter MS; HeartMate II Clinical Investigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5:241-248. doi: 10.1161/CIRCHEARTFAILURE.111.963991.
9. Starling RC, Naka Y, Boyle AJ, Gonzalez-Stawinski G, John R, Jorde U, Russell SD, Conte JV, Aaronson KD, McGee EC Jr, Cotts WG, DeNofrio D, Pham DT, Farrar DJ, Pagani FD. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2011;57:1890-1898. doi: 10.1016/j.jacc.2010.10.062.
10. Alba AC, Agoritsas T, Jankowski M, Courvoisier D, Walter SD, Guyatt GH, Ross HJ. Risk prediction models for mortality in ambulatory patients with heart failure: a systematic review. Circ Heart Fail. 2013;6:881-889. doi: 10.1161/CIRCHEARTFAILURE.112.000043.
11. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Køber L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN; Meta- Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34:1404-1413. doi: 10.1093/eurheartj/ehs337.
12. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113:1424-1433. doi: 10.1161/CIRCULATIONAHA.105.584102.
13. Gorodeski EZ, Chu EC, Chow CH, Levy WC, Hsich E, Starling RC. Application of the Seattle Heart Failure Model in ambulatory patients presented to an advanced heart failure therapeutics committee. Circ Heart Fail. 2010;3:706-714. doi: 10.1161/CIRCHEARTFAILURE.110.944280.
14. Oz MC, Goldstein DJ, Pepino P, Weinberg AD, Thompson SM, Catanese KA, Vargo RL, McCarthy PM, Rose EA, Levin HR. Screening scale predicts patients successfully receiving long-term implantable left ventricular assist devices. Circulation. 1995;92:II169-II173.
15. Cowger J, Sundareswaran K, Rogers JG, Park SJ, Pagani FD, Bhat G, Jaski B, Farrar DJ, Slaughter MS. Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score. J Am Coll Cardiol. 2013;61:313-321. doi: 10.1016/j. jacc.2012.09.055.
16. Cowger JA, Castle L, Aaronson KD, Slaughter MS, Moainie S, Walsh M, Salerno C. The HeartMate II Risk Score: an adjusted score for evaluation of all continuous-flow left ventricular assist devices. ASAIO J. 2016;62:281-285. doi: 10.1097/MAT.0000000000000362.
17. Rogers JG, Boyle AJ, O'Connell JB, Horstmanshof DA, Haas DC, Slaughter MS, Park SJ, Farrar DJ, Starling RC. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: design and rationale of the ROADMAP clinical trial. Am Heart J. 2015;169:205-210.e20. doi: 10.1016/j.ahj.2014.11.004.
18. Kalogeropoulos AP, Georgiopoulou VV, Giamouzis G, Smith AL, Agha SA, Waheed S, Laskar S, Puskas J, Dunbar S, Vega D, Levy WC, Butler J. Utility of the Seattle Heart Failure Model in patients with advanced heart failure. J Am Coll Cardiol. 2009;53:334-342. doi: 10.1016/j. jacc.2008.10.023.
19. May HT, Horne BD, Levy WC, Kfoury AG, Rasmusson KD, Linker DT, Mozaffarian D, Anderson JL, Renlund DG. Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. Am J Cardiol. 2007;100:697-700. doi: 10.1016/j.amjcard.2007.03.083.
20. Dardas T, Li Y, Reed SD, O'Connor CM, Whellan DJ, Ellis SJ, Schulman KA, Kraus WE, Forman DE, Levy WC. Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with heart failure. J Heart Lung Transplant. 2015;34:1017-1023. doi: 10.1016/j. healun.2015.03.017.
21. Adamo LL, Tang Y, Nassif M, Novak E, Jones PG, Larue S, Spertus JA, Mann DL. The HeartMate risk score identifies patients with similar mortality risk across all INTERMACS profiles in a large multicenter analysis. JACC Heart Fail. 2016;4:950-958.